Cannabis Delivery Companies in Florida: Fleet Ownership vs. Subcontracting

nathan_webbmd1

Florida’s medical cannabis market has grown significantly since legalization in 2016, and delivery services have become an essential part of the ecosystem. As patient numbers expand, cannabis companies in Florida are faced with a critical decision: owning their delivery fleet or subcontracting to third-party services. Here’s a look at how delivery operates in Florida’s cannabis industry and some notable examples.

Florida’s Cannabis Delivery Landscape

Florida’s medical cannabis law permits the delivery of cannabis products to registered patients. Delivery is a convenient option for patients who may be unable to visit dispensaries due to medical conditions or geographic limitations. According to the Florida Department of Health’s Office of Medical Marijuana Use (OMMU), over 820,000 medical marijuana patients are registered in the state as of 2024, driving demand for delivery services.

Fleet Ownership vs. Subcontracting

Fleet Ownership

Many of Florida’s prominent cannabis companies operate their own delivery fleets. Owning a fleet allows companies to maintain complete control over their delivery operations, ensuring compliance with Florida’s strict cannabis regulations. Companies that own their delivery fleets must invest in:\n\n- Vehicles equipped with GPS tracking and security measures.\n- Training for drivers to comply with regulatory requirements.\n- Logistics systems to manage delivery routes efficiently.\n\nFor example:\n\n- Trulieve, one of Florida’s largest cannabis operators, manages its own fleet for deliveries across the state. This approach ensures consistent service quality and compliance with state laws.\n- Curaleaf also operates its fleet and offers delivery services statewide, emphasizing patient privacy and product security.\n\n### Subcontracting Delivery Services\nSome cannabis companies choose to subcontract delivery operations to third-party logistics providers. Subcontracting can reduce the burden of fleet management, vehicle maintenance, and compliance, but it comes with its challenges, such as ensuring the third-party provider adheres to Florida’s cannabis laws.\n\nExamples of subcontracting in the industry are less common in Florida compared to other states. The Florida Office of Medical Marijuana Use (OMMU) requires strict documentation and reporting for every delivery, making it challenging for companies to rely heavily on external providers.

Regulations Impacting Delivery Models

Florida’s cannabis delivery laws impose several requirements that influence whether companies own fleets or subcontract:\n\n1. Security Measures: Cannabis deliveries must be tracked with GPS, and products must be transported in locked, secure compartments.\n2. Patient Verification: Drivers must verify patient identification and medical marijuana card validity upon delivery.\n3. Record Keeping: Delivery logs must be maintained for inspections by state regulators.\n4. Delivery Zone Restrictions: Companies must adhere to local ordinances that may restrict cannabis delivery.\n\nThese regulations often push companies toward owning fleets to maintain control and minimize risks.

Challenges and Opportunities

Challenges
  • High Operational Costs: Owning a fleet is expensive due to vehicle maintenance, insurance, and employee wages.\n- Regulatory Burden: Ensuring compliance with Florida’s cannabis delivery laws can be complex.\n\n### Opportunities\n- Customer Loyalty: Direct fleet ownership allows companies to provide a personalized, reliable experience.\n- Market Growth: The expanding medical cannabis patient base creates opportunities for delivery service innovation.\n\n—

Florida’s Delivery

In Florida, most cannabis companies, such as Trulieve and Curaleaf, opt to own their delivery fleets to meet regulatory requirements and maintain control over operations. While subcontracting delivery services is less common, it remains an option for companies looking to minimize logistics management. As the cannabis industry evolves, delivery will continue to be a key driver of patient access and convenience.

Sources